Cancer Therapy News and Research

RSS

Study reveals cancer in humans linked with high amounts of proteins responsible for cells division

Cancer in humans is frequently associated with unusually high amounts of one or more proteins responsible for controlling the rate at which cells divide. As an example, excessive amounts of the cyclin-dependent kinase CDK6 are often found in types of cancer such as lymphoma.

14 Aug 2013

RaySearch Laboratories announces first patient treated with RayStation

RaySearch Laboratories AB announces that the first patient in Australasia has been treated with a treatment plan created with RaySearch's treatment planning system RayStation®. The treatment was carried out at Auckland Radiation Oncology in Auckland, New Zealand.

From Elekta 13 Aug 2013

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Precision Therapeutics will proudly continue its dedicated support to the NOCC Pittsburgh Chapter's 13th Annual Walk to Break the Silence on Ovarian Cancer. Precision has been a strong supporter of the NOCC 5 Mile Run/5 Mile & 1 Mile walk for over five years, and once again expects a great number of its employees will join together in full force to walk alongside ovarian cancer patients and survivors to help strengthen the partnerships it has forged by supporting the very cancer patients that it strives to help.

13 Aug 2013

Women diagnosed for menopause after breast cancer may vary with type of doctors

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees.

13 Aug 2013

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Teva Pharmaceutical Industries Ltd. and Perrigo Company today announced the launch of the generic equivalent to Temodar (temozolomide).

13 Aug 2013

Scientist develop mathematical model that predicts how individuals respond to cancer treatment

Vittorio Cristini, PhD, uses the example of an airplane to explain what he does in cancer research. "Before calculus," he says, "people couldn't really design a plane that would fly. You can do it by trial and error, but it would probably take centuries." Dr. Cristini has a faster way to try to understand cancer treatment. Like airplane designers today, he uses a mathematical model.

13 Aug 2013

Researchers suggest neural stem cells may regenerate after anti-cancer treatment

Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new Johns Hopkins research in mice suggests that neural stem cells, the body's source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like state to reproduce and generate new cells able to migrate, replace injured cells and potentially restore lost function.

13 Aug 2013

Quality of life of young, female cancer survivors is impaired after treatment

A new study led by a University of Colorado Cancer Center member recently published in the journal Quality of Life Research reveals that in young, female cancer survivors, quality of life is significantly impaired long after treatment. The study compared 59 cancer survivors to 66 healthy controls and found that, as expected, cancer survivors showed higher stress and anxiety than the general population.

13 Aug 2013

Researchers explore potential of neural stem cells to repair brain damage

Scientists have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new Johns Hopkins research in mice suggests that neural stem cells, the body’s source of new brain cells, are resistant to radiation, and can be roused from a hibernation-like state to reproduce and generate new cells able to migrate, replace injured cells and potentially restore lost function.

13 Aug 2013

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells to inhibit proliferation. According to BreastCancer.org 1 in 8 women in the U.S. will develop invasive breast cancer and more than 39,000 deaths occur annually.

12 Aug 2013

Celgene's pomalidomide gets approval in UK for multiple myeloma

Celgene confirmed today that Pomalidomide Celgene▼ (pomalidomide), a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland.

9 Aug 2013

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

9 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

8 Aug 2013

NCI renews UCLA prostate SPORE grant

UCLA's Jonsson Comprehensive Cancer Center and the department of urology at the David Geffen School of Medicine at UCLA have been notified that their standing as a National Cancer Institute Specialized Program of Research Excellence site in prostate cancer has been renewed for another five years.

8 Aug 2013

Study could boost development of personalised medicine in cancer care and therapy

A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.

7 Aug 2013

Scientists discover biomarker that helps physicians predict how well cancer patients respond to drugs

A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology (IMCB) have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs.

7 Aug 2013

Study finds cancer survivors do not always have best access to primary care

While cancer survivors require follow-up care to prevent a recurrence of their cancer and to watch for after effects of treatment, they also need the same preventive check-ups suggested for all people.

7 Aug 2013

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

A team of researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center has identified 18 new genes responsible for driving glioblastoma multiforme, the most common-and most aggressive-form of brain cancer in adults. The study was published August 5, 2013, in Nature Genetics.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Cancer Therapy News and Research

Study reveals cancer in humans linked with high amounts of proteins responsible for cells division

RaySearch Laboratories announces first patient treated with RayStation

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Women diagnosed for menopause after breast cancer may vary with type of doctors

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

Scientist develop mathematical model that predicts how individuals respond to cancer treatment

Researchers suggest neural stem cells may regenerate after anti-cancer treatment

Quality of life of young, female cancer survivors is impaired after treatment

Researchers explore potential of neural stem cells to repair brain damage

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Celgene's pomalidomide gets approval in UK for multiple myeloma

Research suggests blocking DNA repair complex helps fight therapy-resistant leukemia

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

NCI renews UCLA prostate SPORE grant

Study could boost development of personalised medicine in cancer care and therapy

Scientists discover biomarker that helps physicians predict how well cancer patients respond to drugs

Study finds cancer survivors do not always have best access to primary care

Columbia researchers identify 18 new genes that drive glioblastoma multiforme

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News